Press Releases
Press Release
2011, October 12th
OctreoPharm Sciences Receives Orphan Drug Designation for SOMscan® for the Diagnosis of Neuroendocrine Tumours
OctreoPharm Sciences GmbH, a Berlin based specialist for radiopharmaceuticals, announced today that the European Medicines Agency has granted Orphan Drug status to OctreoPharm Sciences product SOMscan® for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.
Press Release
2011, October 6th
OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product
OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear medical pharmaceuticals (radiopharmaceuticals), announced today that it has received the worldwide exclusive license for the development and commercialization of SOMscan™, from Novartis Pharma AG.
Press Release
2011, May 17
EMA Grants SME Status to OctreoPharm Sciences GmbH
OctreoPharm Sciences GmbH, a medicine developer and specialist for radio contrast agents in nuclear medicine has been granted SME status as small-sized enterprise in research and development by the European Medicine Agency EMA.
Press Release
2011, April 6th
OctreoPharm Sciences GmbH closes Financing Round for Cancer Diagnostic
OctreoPharm Sciences GmbH, a specialist for nuclear-medical contrast mediums, was able to successfully close a financing round for the clinical development of its cancer diagnostic SOMscan®.